3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Pulmonary Nodules
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Barrett Esophagus
1
Adenocarcinoma
1
Interventions
Carboplatin
42
Etoposide
37
Cisplatin
23
Topotecan
22
Nivolumab
17
pembrolizumab
12
atezolizumab
12
Ipilimumab
10
Paclitaxel
9
durvalumab
8
Irinotecan
8
Radiosurgery
6
Pemetrexed
6
rovalpituzumab tesirine
5
Magnetic Resonance Spectroscopy
5
trioctyl phosphine oxide
4
trilaciclib
4
etoposide phosphate
4
berzosertib
4
Sunitinib
4
Specimen Handling
4
Platinum
4
PM 01183
4
Dexamethasone
4
veliparib
3
tremelimumab
3
olaparib
3
carfilzomib
3
cabozantinib
3
Temozolomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Small Cell Lung Carcinoma
×
Diagnostic Imaging
×
Clear all
NCT00047385
2014-05-20
NLST
National Cancer Institute (NCI)
Phase 3
Completed
53,454 enrolled
15 charts